Sofosbuvir‐based regimens for the treatment of hepatitis C virus in patients who underwent lung transplant: case series and review of the literature

BACKGROUND: Chronic infection with HCV can rapidly progress to cirrhosis leading to increased mortality rates in immunosuppressed organ-transplanted patients. In liver-transplanted patients, the introduction of directly acting antivirals has modified HCV natural history by providing a safe and effective therapy for this group of patients. To date there are no data on safety and efficacy of IFN-free regimens in HCV patients who received lung transplant (LuT). METHODS: We report three patients who have received anti-HCV treatment after LuT with Sofosbuvir-based regimens. RESULTS: All patients achieved a SVR, no unexpected safety signals were observed and no modifications in immunosuppressants were required. CONCLUSIONS: Our report is the first to show that HCV patients who underwent LuT can be safely treated with IFN-free regimens, thus opening the door for refined clinical management of this category of patients.